Expanding Alzheimer’s research

Alzheimer’s disease has long posed a challenge for clinicians and researchers because it develops quietly and unfolds over many years. The biological changes begin well before symptoms appear, making the disease difficult to detect early and even harder to measure at scale. Conventional diagnostic tools such as cerebrospinal fluid testing and PET imaging, while informative, are costly, invasive and out of reach for much of the global population. Recent progress in blood-based biomarkers is beginning to change this reality. Advances involving phosphorylated tau at amino acid 217, commonly known as p-tau217, are reshaping how Alzheimer’s disease can be identified and studied at the population level. What was once limited to specialised research settings is now approaching real-world applicability.

Blood biomarkers in large-scale studies

Historically, estimates of Alzheimer’s prevalence have depended on clinic-based samples, cognitive testing or post-mortem examinations. While valuable, these approaches have offered only a partial picture, leaving uncertainty about how common Alzheimer’s pathology truly is among people living in the community. Large-scale population studies are now addressing this gap by using blood tests to measure Alzheimer’s biomarkers in thousands of individuals. These efforts represent a fundamental shift from studying small, selected groups to assessing biological disease markers across entire populations. One notable example comes from a large Norwegian cohort that included more than 11,000 adults aged 58 and older.¹ Researchers measured plasma p-tau217, a biomarker closely linked to Alzheimer’s-related neuropathological change. The findings showed a clear and progressive increase in prevalence with age:

• Fewer than 8 percent of adults between ages 58 and 69 tested positive
• More than one third of individuals aged 70 and older showed elevated p-tau217
• Among those aged 90 and above, prevalence reached levels previously suggested only by neuropathology studies

Crucially, elevated biomarkers were not confined to individuals with cognitive symptoms. Many cognitively unimpaired participants also showed biological signs of Alzheimer’s pathology, underscoring how the disease can remain hidden long before dementia becomes clinically evident.

The impact of blood-based testing

Blood biomarkers for Alzheimer’s disease, especially those measuring p-tau217 and amyloid ratios, have advanced rapidly in recent years.^2–4 What were once experimental tools are now approaching clinical relevance because they offer several key advantages:

• They are minimally invasive and scalable, relying on a standard blood draw rather than lumbar puncture or advanced imaging
• They demonstrate strong sensitivity when compared with established brain pathology markers, with plasma p-tau217 closely mirroring changes seen in the brain
• They can be deployed widely across populations, which is essential for generating reliable epidemiological data

Together, these strengths make it possible to estimate Alzheimer’s prevalence based on underlying biology rather than observed symptoms alone. This distinction is critical for accurate public health planning.

A new public health lens

Population-based biological data has far-reaching implications. For public health leaders, more accurate estimates of Alzheimer’s pathology enable better planning for healthcare infrastructure, long-term care services and caregiver support. For clinicians, earlier biological detection may help inform decisions about when to introduce therapies aimed at slowing cognitive decline, well before symptoms appear. For researchers, blood tests simplify recruitment and broaden participation in clinical trials, including among groups that have historically been underrepresented. There are also important equity implications. Less invasive and more accessible testing could reduce disparities in Alzheimer’s detection and allow earlier identification across diverse communities worldwide. Taken together, these developments point toward a fundamental reframing of Alzheimer’s disease. Rather than being viewed solely as a late-stage clinical diagnosis, it can be understood as a measurable population health condition, similar to how blood pressure transformed the management of cardiovascular disease.

Despite the promise, important challenges remain. A positive biomarker result reflects underlying neuropathological change, but it does not guarantee that an individual will develop dementia. This distinction is essential for clinical decision-making and for conversations with patients and families. As with other predictive biomarkers, careful interpretation and appropriate counselling are critical. Health systems must also be prepared for the consequences of large-scale detection. Identifying Alzheimer’s pathology earlier will increase demand for follow-up care, monitoring and potentially treatment. In addition, most large studies to date have been conducted in relatively homogeneous populations, highlighting the need for broader validation across diverse genetic, cultural and environmental contexts.

Future promise

The direction of Alzheimer’s research increasingly points toward the integration of blood-based testing into routine practice. In the future, assessing Alzheimer’s pathology could become part of standard health evaluations for older adults. Achieving this will require close collaboration among researchers, clinicians, policymakers and health systems to establish ethical standards, cost-effective implementation strategies and clear educational guidance for both professionals and the public. Blood tests for Alzheimer’s are not simply new diagnostic tools. They offer a new lens through which the true scale and progression of the disease can be understood. As this field continues to evolve, it has the potential to reshape how Alzheimer’s disease is measured, anticipated and ultimately addressed as one of the defining health challenges of the twenty-first century.

By Dr Azhaar Ashraf

References

1. Aarsland D, Sunde AL, Tovar-Rios DA, et al. Prevalence of Alzheimer's disease pathology in the community. Nature. Published online December 17, 2025. doi:10.1038/s41586-025-09841-y.
2. Kim KY, Shin KY, Chang KA. Blood-Based Tau as a Biomarker for Early Detection and Monitoring of Alzheimer's Disease: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2025;26(21):10330.
3. Barthélemy NR, Salvadó G, Schindler SE, et al. Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med. 2024;30(4):1085–1095.
4. Grande G, Valletta M, Rizzuto D, et al. Blood-based biomarkers of Alzheimer's disease and incident dementia in the community. Nat Med. 2025;31(6):2027–2035.